Eric Delarge, general manager and representative director of Servier Japan, recently became the first member of the international pharma industry to join bioIPSeeds, an innovative tool aiming to foster early stage collaboration between academia and the global industry, which also stands as the first application of the blockchain technology in the pharmaceutical and healthcare fields. In this regard, he provides insights into the main hurdles he usually faces as part of his scouting and screening activities across the region, as well as his expectations regarding the heightened collaboration potential that a blockchain-based platform such as bioIPSeeds could offer.
As general manager and representative director of Servier Japan, why is industry-academia collaboration important to you?
"Despite Japan’s efforts to improve translational research and bring academia closer to the industry, bioIPSeeds actually perfectly embodies the kind of pioneering tool that could benefit Japanese researchers."
